J
Jean Luc Harousseau
Researcher at University of Nantes
Publications - 82
Citations - 16270
Jean Luc Harousseau is an academic researcher from University of Nantes. The author has contributed to research in topics: Multiple myeloma & Bortezomib. The author has an hindex of 46, co-authored 82 publications receiving 14925 citations. Previous affiliations of Jean Luc Harousseau include University of Pennsylvania & Hotel Dieu Hospital.
Papers
More filters
Journal Article
13q14 deletions are not primary events in B-cell chronic lymphocytic leukemia : A study of 100 patients using fluorescence in situ hybridization
Hervé Avet-Loiseau,Marie-Claire Devilder,Richard Garand,I Bouyge,M. J. Rapp,Noel Milpied,Jean Luc Harousseau,Jean-Paul Moisan,Régis Bataille +8 more
TL;DR: The data confirm that the 13Q14 deletion is a frequent event, indicate that the concomitant occurrence of 13q14 deletion and trisomy 12 is rare but possible, and show that both abnormalities are secondary events in B-cell chronic lymphocytic leukemia.
Journal ArticleDOI
Is ASCT with TBI superior to ASCT without TBI in mantle cell lymphoma patients
Pierre Peterlin,Christophe Leux,Thomas Gastinne,Virginie Roland,Beatrice Mahe,Viviane Dubruille,Jacques Delaunay,Patrice Chevallier,Thierry Guillaume,Nicolas Blin,Sameh Ayari,Aline Clavert,Mohamad Mohty,Christelle Dousset,Noel Milpied,Jean Luc Harousseau,Philippe Moreau,Soraya Wuilleme,Anne Moreau,Steven Le Gouill +19 more
TL;DR: It is shown that transplant patients with MCL remain highly exposed to relapse, and the absence of TBI in conditioning regimen modifies neither PFS nor OS.
Journal ArticleDOI
High dose radiochemotherapy followed by autologous stem cell transplantation in four patients with multiple lymphomatous polyposis.
Béatrice Mahé,Anne Moreau,Philippe Moreau,Stephane Le Tortorec,Jean Luc Harousseau,Noel Milpied +5 more
TL;DR: High dose radiochemotherapy with autologous stem cell transplantation with ASCT, which is one of the most intensive treatments of lymphoma, to the authors' knowledge has not been evaluated in the treatment of MLP.
Journal ArticleDOI
Treatment of acute non-lymphoblastic leukaemia in elderly patients
Journal ArticleDOI
Bortezomib (BOR) and High Dose Melphalan (HDM) as Conditioning Regimen Before Autologous Stem Cell Transplantation (ASCT) for De Novo Multiple Myeloma (MM): Final Results of the IFM Phase II Study VEL/MEL
Murielle Roussel,Anne Huynh,Philippe Moreau,Jean Luc Harousseau,Cyrille Hulin,Denis Caillot,Christophe Fruchart,Gerald Marit,Brigitte Pegourie,Michel Attal +9 more
TL;DR: It is suggested that BOR (1 mg/m2) and HDM is a safe and highly effective conditioning regimen in frontline MM pts with almost 70% achieving Complete Response (CR) and VGPR at 3 months post ASCT.